NCT03459222 2025-04-02
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
11 trialsNCT02935634 2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2 Completed
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT02996110 2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2 Completed
NCT03792750 2022-02-28
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT03386838 2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT03192943 2019-04-01
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03417037 2018-04-30
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT03312426 2018-01-19
An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants
Bristol-Myers Squibb
Phase 1 Completed
NCT03247283 2017-11-06
Pharmacokinetics and Metabolism Study in Healthy Male Participants
Bristol-Myers Squibb
Phase 1 Completed